Renhe Pharmacy Co Ltd

Renhe Pharmacy maintains a strong liquidity position, with a current ratio of 5.24, indicating the company can easily cover its short-term obligations with its current assets. The company's liquidity_fpt score is high, supported by a positive operating cash flow of 360.72 million CNY and a negligible long-term debt of 9.09 million CNY. However, the risk assessment notes that net cash is negative after subtracting total debt, suggesting potential short-term liquidity constraints.

Profitability metrics show a return on equity (ROE) of 2.54% and a return on assets (ROA) of 1.99%, both below the industry median for pharmaceutical companies. The company's gross profit margin is 39.2%, and its operating margin is 24.8%, which are in line with the sector average. However, the net profit margin of 14.2% is slightly below the median, indicating potential inefficiencies in cost management or pricing power.

Geographically, Renhe Pharmacy's revenue is concentrated in China, with no disclosed international operations. The company's revenue is derived from a single business segment, which increases its exposure to domestic regulatory and economic risks. The lack of diversification in both product and geographic markets could limit its ability to weather regional downturns or policy shifts.

Looking ahead, the company is expected to grow its revenue from 1.13 billion CNY in the current fiscal year to 3.82 billion CNY in the next fiscal year, according to analyst estimates. This represents a significant year-over-year increase of 239.3%. However, the company's capital expenditures are negative at -176.79 million CNY, suggesting a reduction in investment in new facilities or equipment. This could signal a shift in strategy or a focus on cost-cutting rather than expansion.

The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.0, indicating no leverage, which is a positive sign for financial stability. However, the negative net cash position after subtracting total debt suggests that the company may need to raise additional capital in the near term to maintain its liquidity. The dilution risk is low, with no near-term pressure expected, and the company's shares outstanding have not changed between basic and diluted shares.

Recent events include the release of the latest financial data, which shows a strong operating cash flow and a significant increase in analyst revenue estimates. The company has not disclosed any major new product launches or strategic partnerships in the most recent filings. The absence of recent capital-raising activities or major regulatory changes suggests a stable but potentially conservative operational approach.

Renhe Pharmacy Co Ltd (000650.SZ) has been formally classified within the Healthcare economic sector and the Pharmaceuticals activity category, marking a significant update to its corporate taxonomy. This classification provides a clearer structural definition of the company’s operational focus, aligning its profile with industry-specific benchmarks and facilitating more precise sector-based analysis for investors and analysts. In terms of risk assessment, the company now exhibits a low dilution risk, indicating a stable capital structure with minimal threat of share value erosion from new issuances. This low dilution risk is a positive signal for existing shareholders, suggesting that management is likely prioritizing capital efficiency and protecting current equity interests. Conversely, the risk assessment identifies a medium liquidity risk, highlighting potential challenges in converting assets to cash or meeting short-term obligations without significant cost. This medium liquidity risk warrants attention, as it may impact the company’s operational flexibility and its ability to respond swiftly to market changes or investment opportunities within the pharmaceutical sector. The COMPANY_360 data indicates zero analyst coverage, index memberships, and top holders, alongside an officer count of zero in the current dataset. This lack of external coverage and holder data suggests that Renhe Pharmacy may be a less followed entity in the market, potentially offering opportunities for investors who can conduct deeper independent due diligence on its financials and estimates.

The company maintains a zero debt-to-equity ratio, significantly outperforming the 0.18 median leverage of its pharmaceutical peers.

Cash conversion ratio of 2.26 is well above the 0.95 cohort median, indicating superior cash generation efficiency.

Free cash flow surged 159.5% year-over-year to CNY 316 million, demonstrating strong recent liquidity generation.

Low dilution and credit risk flags suggest a stable capital structure with minimal immediate financial distress indicators.

Medium liquidity risk flag suggests potential challenges in meeting short-term obligations despite strong cash flow.